［1］ANSELL J，HIRSH J，POLLER L，etal．The pharmacology and management of the vitamin K antagonists：the seventh ACCP con⁃ference on antithrombotic and thrombolytic therapy．Chest，2004，126（3）：204⁃233．

［2］许俊堂，胡大一．使用口服抗凝药物出血的处理与预防．中国医药导刊，2001，3（5）：361⁃362．

［3］GOLDHABER S Z．Modern treatment of pulmonary embolism．Eur Respir J Suppl，2002，35：22⁃27．

［4］BECATTINI C，VEDOVATI MC，AGNELLI G，et al．Old and new oral anticoagulants for venous thromboembolism and atrial fi⁃brillation：A review of the literature．Thromb Res，2012，129（3）：392⁃400．

［5］PERZBORN E，STRASSBURGER J，WILMEN A，et al．In vitro and in vivo studies of the novel antithrombotic agent BAY 59⁃7939⁃⁃an oral，direct factorⅩa inhibitor［J］．JThromb Haemost，2005，3（3）：514⁃521．

［6］ROEHRIG S，STRAUB A，POHLMANN J，etal．Discovery of the novel antithrombotic agent5⁃chloro⁃N：an oral，direct factorⅩa inhibitor．JMed Chem，2005，22，48（19）：5900⁃5908．

［7］KUBITZ A D，BECKA M，VOITH B，et al．Safety，pharmacodynamics，and pharmacokinetics of single doses of BAY 59⁃7939，an oral，direct factorⅩa inhibitor．Clin Pharmacol Ther，2005，78（4）：412⁃421．

［8］KUBITZA D，BECKA M，WENSING G，et al．Safety，pharmacodynamics，and pharmacokinetics of BAY 59⁃7939⁃⁃an oral，direct FactorⅩa inhibitor⁃⁃aftermultiple dosing in healthymale subjects．Eur JClin Pharmacol，2005，61（12）：873⁃880．

［9］AHMAD Y，LIPGY．Stroke Prevention in Atrial Fibrillation：Where are We Now？．Clin Med Insights Cardiol，2012，6：65⁃78．

［10］HANKEY GJ，PATELMR，STEVENSSR，etal．Rivaroxaban compared with warfarin in patientswith atrial fibrillation and pre⁃vious stroke or transient ischaemic attack：a subgroup analysis of ROCKET AF．Lancet Neurol，2012，11（4）：315⁃322．

［11］许俊堂，胡大一，唐朝枢，等．内皮素⁃内皮素受体在凝血酶促进血管平滑肌细胞增殖中的作用．微循环杂志，2002，12：38⁃39．

［12］许俊堂，唐朝枢，张波，等．不同损伤时期血管内膜的增殖和凝血酶的影响．中国循环杂志，1999，14：289⁃291．

［13］LaMonte MP．Argatroban in thrombotic stroke．Pathophysiol Haemost Thromb，2002，32（suppl 3）：39⁃45．

［14］Lewis BE，MatthaiWH Jr，Cohen M，et al．ARG⁃216/310/311 Study Investigators．Argatroban anticoagulation during percutane⁃ous coronary intervention in patients with heparin⁃induced thrombocytopenia．Catheter Cardiovasc Interv，2002，57：177⁃184．

［15］Howell MD，Powers RD．Utility of thrombocytopenia as a marker for heparin allergy in adult ED patients．Am J Emerg Med．2006，24（3）：268⁃270．

［16］Jappe U，Juschka U，Kuner N，et al．Fondaparinux：a suitable alternative in cases of delayed⁃type allergy to heparins and semi⁃synthetic heparinoids？A study of 7 cases．Contact Dermatitis．2004，51（2）：67⁃72．

［17］孙雪峰．如何选择血液透析的抗凝治疗方案．中国血液净化，2008，7（6）：335⁃337．

［18］Kubitza D，Becka M，Mueck W，et al．Effects of renal impairment on the pharmacokinetics，pharmacodynamics and safety of ri⁃varoxaban，an oral，direct Factor a inhibitor．Br JClin Pharmacol．2010，70（5）：703⁃712．

［19］EINSTEIN Investigators，Bauersachs R，Berkowitz SD et al．Oral rivaroxaban for symptomatic venous thromboembolism．N Engl JMed，2010，363：2499⁃2510．

［20］Eikelboom JW，Mehta SR，Anand SS，et al．Adverse impactof bleeding on prognosis in patientswith acute coronary syndromes．Circulation，2006，114：774⁃782．

［21］Eikelboom JW，Quinlan DJ，Mehta SR，etal．Unfractionated and low⁃molecular⁃weightheparin as adjuncts to thrombolysis in as⁃pirin⁃treated patients with ST⁃elevation acutemyocardial infarction：ameta⁃analysis of the randomized trials．Circulation．2005，112（25）：3855⁃3867．

［22］Stone GW，Witzenbichler B，GuagliumiG，et al．Bivalirudin during primary PCI in acutemyocardial infarction．N Engl JMed，2008，358（21）：2218⁃2230．

［23］Mehran R，Lansky AJ，Witzenbichler B，et al．Bivalirudin in patients undergoing primary angioplasty for acutemyocardial in⁃farction（HORIZONS⁃AMI）：1⁃year results of a randomised controlled trial．HORIZONS⁃AMITrial Investigators．Lancet，2009，374（9696）：1149⁃1159．

［24］Stone GW，Witzenbichler B，Guagliumi G，et al．Heparin plus a glycoproteinⅡb/Ⅲa inhibitor versus bivalirudin monotherapy and paclitaxel⁃eluting stents versus bare⁃metal stents in acute myocardial infarction（HORIZONS⁃AMI）：final 3⁃year results from amulticentre，randomised controlled trial．

［25］O’Gara PT，Kushner FG，Ascheim DD，et al．2013 ACCF/AHA guideline for the management of ST⁃elevation myocardial in⁃farction：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guide⁃lines．American College of Emergency Physicians；Society for Cardiovascular Angiography and Interventions．JAm Coll Cardiol，2013，61（4）：e78⁃140．

［26］Steg PG，James SK，Atar D，et al．ESCGuidelines for themanagement of acute myocardial infarction in patients presenting with ST⁃segment elevation．Task Force on the management of ST⁃segment elevation acute myocardial infarction of the European Soci⁃ety of Cardiology（ESC）．Eur Heart J．2012，33（20）：2569⁃2619．

［27］Shahzad A，Kemp I，Mars C，et al．Unfractionated heparin versus bivalirudin in primary percutaneous coro nary intervention（HEAT⁃PPCI）：an open⁃label，single centre，randomised controlled trial．Lancet，2014，22；384（9957）：1849⁃1858．

［28］Schulz S，Richardt G，Laugwitz KL，et al．Bavarian Reperfusion Alternatives Evaluation（BRAVE）4 Inve stigators．Eur Heart J，2014，35（34）：2285⁃2294．

［29］Steg PG1，van’t Hof A，Hamm CW，etal．Bivalirudin started during emergency transport for primary PCI．N Engl JMed．2013，369（23）：2207⁃2217．

［30］Stone GW，Ware JH，Bertrand ME，et al．Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasivemanagement：one⁃year results from the ACUITY trial．JAMA，2007，298（21）：2497⁃2506．

［31］Linoff AM，Bittl JA，Harrington RA，etal．Bivalirudin and provisional glycoproteinⅡb/Ⅲa blockade compared with heparin and planned glycoprotein Ⅱb/Ⅲa blockade during percutaneous coronary interventi on：REPLACE⁃2 randomized trial．JAMA，2003，289（7）：853⁃863．

［32］Adnan Kastrati，M．D．，Franz⁃Josef Neumann，et al．Bivalirudin versus heparin in patients planned for percutaneous coronary in⁃tervention：a meta⁃analysis of randomised controlled trials．N Engl JMed，2008，359：688⁃696．